Retina

Uwe Oberheide, MD, discusses the key findings of his virtual ARVO 2021 presentation on modeling of IOLs for patients with AMD by ray-tracing.

Preexisting neutralizing antibodies associated with the inflammatory changes.

Fluocinolone acetonide implant for DME benefits visual acuity.

Injections, implants continue to create further positive outcomes for patients.

Eyes with chronic disease responded to steroid treatment.

Studying zebrafish helps unravel mysteries of photoreceptor regeneration .

‘Revolutionary Eye and Vision Research’ theme of annual meeting.

Studies are uncovering a range of potential treatment options for disorders.

Options for physicians are increasing in availability with fewer burdens for patients.

Minimizing clinic visits, maximizing use of imaging modalities are key.

Physician offers patient counseling pearls for selected retinal diseases.

During the trial, a patient gained vision, which lasted more than a year, after a single injection of an experimental RNA therapy into the eye.

Mary Elizabeth Hartnett, MD, FACS, FARVO, and Mark Breazzano, MD, discuss current research being conducted involving AMD and maximizing patient outcomes amid the pandemic.

Study highlights role of demographic and socioeconomic characteristics in treatment.

The results from Diabetic Retinopathy Clinical Research Network protocols have become the standard of care for treating DME and proliferative diabetic retinopathy.

Option demonstrates stable to improved visual acuity and retinal thickness.

Rapid fluid identification may result in better visual outcomes.

SemaThera Inc. has announced a research collaboration and licensing agreement with Roche to develop a new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases.

Investigators observe dramatic decrease in treatment burden seen in OPTIC study.

Protocol V delves into observation of disease.

Investigators set out to determine if treatment crosses blood-retina barrier.

Technology helps physicians understand normal and abnormal macular anatomy.

Graybug Vision, Inc. has reported preliminary topline data from a 12-month treatment phase of its Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet AMD.

Transient sensory-motor abnormalities are often common.